tradingkey.logo

Caris Life Sciences Inc

CAI
查看详细走势图
30.380USD
-0.800-2.57%
收盘 11/04, 16:00美东报价延迟15分钟
8.54B总市值
亏损市盈率 TTM

Caris Life Sciences Inc

30.380
-0.800-2.57%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-2.57%

5天

0.00%

1月

-4.41%

6月

0.00%

今年开始到现在

0.00%

1年

0.00%

查看详细走势图

TradingKey Caris Life Sciences Inc股票评分

单位: USD 更新时间: 2025-11-04

操作建议

当前公司基本面数据相对非常健康,公司估值合理,机构认同度非常高,近一月多位分析师给出公司评级为强力买入。公司市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Caris Life Sciences Inc评分

相关信息

行业排名
83 / 210
全市场排名
184 / 4616
所属行业
医疗设备与耗材

压力支撑

暂无数据

多维评测

本期评分
上期评分

分析师目标

根据 8 位分析师
强力买入
评级
39.125
目标均价
+30.68%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Caris Life Sciences Inc亮点

亮点风险
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
估值合理
公司最新PE估值0.00,处于3年历史合理位
机构加仓
最新机构持股130.22M股,环比增加49.73%
菲利普·拉丰持仓
明星投资者菲利普·拉丰持仓,最新持仓市值10.14M

Caris Life Sciences Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

暂无数据

营业总收入

暂无数据

Caris Life Sciences Inc简介

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
公司代码CAI
公司Caris Life Sciences Inc
CEOMr. David Dean Halbert
网址https://www.carislifesciences.com/
KeyAI